Insider Selling: RxSight, Inc. (NASDAQ:RXST) Insider Sells 3,100 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $53.19, for a total transaction of $164,889.00. Following the transaction, the insider now owns 42,246 shares in the company, valued at $2,247,064.74. The sale was disclosed in a filing with the SEC, which is available through this link.

Ilya Goldshleger also recently made the following trade(s):

• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Performance

RxSight stock opened at $48.89 on Wednesday. RxSight, Inc. has a fifty-two week low of $20.66 and a fifty-two week high of $66.54. The company has a market cap of $1.81 billion, a PE ratio of -38.80 and a beta of 1.22. The business’s 50-day simple moving average is $51.02 and its two-hundred day simple moving average is $53.90.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. The company had revenue of $34.89 million during the quarter, compared to analyst estimates of $32.33 million. RxSight had a negative net margin of 31.92% and a negative return on equity of 19.33%. RxSight’s revenue for the quarter was up 67.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) EPS. As a group, analysts predict that RxSight, Inc. will post -0.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Oppenheimer reduced their price objective on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price target on shares of RxSight in a research report on Friday, September 13th. Wells Fargo & Company dropped their target price on RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. BTIG Research upped their target price on RxSight from $72.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Stifel Nicolaus lowered their price target on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, RxSight currently has a consensus rating of “Buy” and a consensus price target of $60.14.

Institutional Investors Weigh In On RxSight

Several hedge funds have recently added to or reduced their stakes in the business. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of RxSight during the 2nd quarter valued at about $3,670,000. Cim LLC purchased a new position in RxSight during the second quarter valued at approximately $476,000. Truist Financial Corp lifted its holdings in RxSight by 11.1% in the second quarter. Truist Financial Corp now owns 5,827 shares of the company’s stock valued at $351,000 after acquiring an additional 583 shares during the period. Point72 Asset Management L.P. boosted its position in RxSight by 279.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 62,935 shares of the company’s stock worth $3,787,000 after purchasing an additional 46,336 shares in the last quarter. Finally, Doheny Asset Management CA boosted its position in RxSight by 51.7% in the 2nd quarter. Doheny Asset Management CA now owns 14,490 shares of the company’s stock worth $872,000 after purchasing an additional 4,940 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.